NFT
BCAX

Nan Fung Trinity’s Bicara Therapeutics BCAX Stock Holding History

Nan Fung Trinity’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.51M Buy
427,885
+55,500
+15% +$955K 0.93% 41
2025
Q4 		$6.27M Sell
372,385
-12,500
-3% -$213K 0.5% 59
2025
Q3 		$6.08M Buy
384,885
+42,000
+12% +$470K 0.61% 50
2025
Q2 		$3.19M Buy
+342,885
New +$4.09M 0.38% 51

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Nan Fung Trinity's BCAX Position: Q1 2026 in Review

Nan Fung Trinity increased its Bicara Therapeutics (BCAX) stake by 15% in Q1 2026, buying an estimated $955K and bringing the position to 427,885 shares worth $8.51M. The position accounts for 0.93% of the portfolio, ranked #41.

Nan Fung Trinity first reported a position in BCAX in Q2 2025 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Nan Fung Trinity held 427,885 shares of Bicara Therapeutics worth $8.51M as of Q1 2026.
  • Nan Fung Trinity bought 55,500 Bicara Therapeutics shares in Q1 2026, an estimated $955K.
  • Bicara Therapeutics made up 0.93% of Nan Fung Trinity's portfolio in Q1 2026, its #41 holding.
  • Nan Fung Trinity first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Nan Fung Trinity's 13F filing for Q1 2026, filed 5 May 2026.